The leader in quality education and networking through//conferences, courses and custom training
Connect with IBC Life Sciences:
- Home
- Events
- TIDES: Oligonucleotide...
- Event Overview
Registration
Download Brochure
Related Events
-
May 20-23, 2012 -
May 20-23, 2012
Find Another IBC Event
TIDES: Oligonucleotide and Peptide® Research, Technology and Product Development
CSS
Alt Language
Alternate Language Options:
Event Overview
Recently, we asked the world-class TIDES speaker faculty to share some interesting facts about themselves that not too many people know. We compiled the 10 most fascinating responses below. We find them pretty amusing and hope you will too.
10 Things You Wouldn't Guess About the TIDES 2012 Faculty
- Can you guess which speaker was once a champion pig carcass judge at age 18?
- Which speaker played piano professionally in a jazz group at age 14?
- Who wanted to grow up to be a motivational speaker for Walt Disney?
- Do you know which speaker was once an ice skating instructor?
- Which speaker had the childhood ambition of becoming a 5-star cook?
- Can you guess which speaker was the lead guitarist for the rock band Spoilt Brats, recognized for his twin-necked electric guitar, as well as his long hair and beard?
- Who wanted to grow up to become an Elite Commando/World Champion in Tang Soo Do?
- Which speaker grew up in Alaska with the childhood desire to become a professional snowplow driver?
- Which speaker wanted to become an astronaut as a youngster?
- Which speaker is a deacon at his church, as well as a fan of Old Spice deodorant?
Looking for the answers?
» Find them on the answers page
Keynote Presentations
Therapeutic Oligonucleotide Development: A Promising Outlook
Arthur M. Krieg, M.D., President and Chief Executive Officer, RaNA Therapeutics, Inc.
Resources to Enable and Facilitate siRNA Drug Development in China
Zicai Liang, Ph.D., Chairman, Suzhou Ribo Life Science Co., LTD, China
Harnessing the "New" Endocrinology of Peptide Hormones - Discovery of Novel Therapies Targeting Metabolic Disease
David E. Moller, M.D., Vice President, Endocrine and Cardiovascular Research and Clinical Investigation, Lilly Research Laboratories, Eli Lilly and Co.
RaPID Discovery of Natural Product-Like Peptides against Therapeutic Targets
Hiroaki Suga, Ph.D., Professor, Chemical Biology and Biotechnology Lab, The University of Tokyo, Japan
The Next Generation in Clinical Molecular Diagnostics
Trevor Hawkins, Ph.D., CEO, Next Generation Diagnostics, Siemens Healthcare Diagnostics
Update on Commercialization of RUO and IUO Products and Oversight of Lab-Developed Tests
Sam Rua, VP, Regulatory Affairs and Quality Systems, HTG Molecular Diagnostics, Inc.
Oligonucleotide and Peptide Manufacturing Technology and Product Development
Case Studies on CMC Challenges, Early Drug Product Development and Delivery Alternatives
Plan for the future as you enjoy a dynamic keynote session including:
- A bright forecast for oligonucleotide therapeutic progress despite recent pharma changes
- An analysis of RNAi activities in China which will form the new "RNAi Valley"
- Strategies to leverage current technology platforms to target best-in-class therapeutics based on peptide hormones
- A report on re-programming the genetic code for discovery of peptide therapeutics.
- Hear updates on the clinical progress of the most promising peptide and oligonucleotide therapeutics in reports from Novartis, Ironwood, Affymax, Regado, Alnylam, Dynavax and Excaliard.
- Benchmark your development activities against the experts by hearing case studies on CMC Challenges and Solutions from Pfizer, Prosensa, Emergent BioSolutions, Bachem and RAPID Laboratories
- Discover more patient-friendly delivery routes from Alnylam, TransDerm, Dynavax, Pfizer, MannKind Corporation and Amunix - to help you gain market share and understand manufacturing challenges with these systems
- Play an active role in moving the industry forward by learning and interacting in Strategy Discussion Forums on critical issues such as analysis of impurities, alternative delivery routes, conjugation, Quality by Design, strategies for formulation transition, and recombinant vs. synthetic production of peptides.
Oligonucleotide Therapeutics Discovery
Improving Drug-Like Properties to Accelerate Preclinical and Clinical Development
- Oligonucleotide delivery mechanisms and targeting
- Chemical modifications to improve drug-like properties
- New data from multiple preclinical and clinical studies
- miRNA inhibitors and non-coding RNA's
- Antisense, siRNA, LNA, aptamers, immune modulation
- Strategies to improve tissue and cellular uptake
Peptide Discovery and Development
Exploiting Peptides as Intracellular Drugs, Novel Scaffolds and Improved Molecules for Therapeutic Development
- CPP's with intrinsic functional activity
- Novel peptide-like scaffolds and structures
- Creative peptide engineering, design and optimization
- Cell-penetrating and membrane-permeable peptides
- New approaches to making drug-like and improved peptides
- Peptides modulating novel targets & disease mechanisms
Nucleic Acids Technologies for Molecular Diagnostics
Accelerating Product Development through Cutting Edge Regulatory, Business and Technology Strategies
- Intellectual Property Challenges in the Diagnostics Industry
- Launch of a Gene Scanning Platform from Canon
- Next Generation Sequencing, Sample Prep and Other New Technology Update
- Co-Development of a Companion Diagnostic from Roche Molecular Systems
- Update on personalized medicine initiatives at Abbott Molecular
- Updates on Ultra HPLC from Roche and Merck
Here's what other attendees said about TIDES
"TIDES is an excellent opportunity to gain knowledge into the vastly expanding area of peptides and oligonucletides. Furthermore, it gives attendees an invaluable chance for networking and building relationships with other experts in the field." -Barry P. O'Connor, Ph.D., Research Scientist, R&D, Sekisui Medical Co., LTD., Japan
"I've looked over the entire agenda and the TIDES 2012 seems like it will be one of the best, if not THE best, meeting I'll attend in 2012." - Richard A. Montagna, Ph.D., Senior Vice President for Corporate Business Development & Scientific Affairs, Rheonix, Inc.
"I have never heard so many good lectures in so little time. Excellent program! Would go again next year." - Peter Timmerman, Chief Technology Officer, Pepscan Therapeutics
"TIDES 2011 was a very productive conference. I had lots of good meetings, with many types of companies. The marriage of the conferences on discovery and manufacturing will make this event a must be for people interested in the TIDES, particularly the oligonucleoTIDES field." - Sven Klussmann, Ph.D., Chief Scientific Officer, NOXXON Pharma AG, Germany
"The TIDES 2011 Conference was a very well organised event. I enjoyed the conference and found it a very good networking platform with vendors and other attendees from various pharmaceutical companies. I shared my latest data in a poster presentation which sparked off some interesting conversations, and I will be applying my learning's from the conference in my day to day investigations." - Nainesh Patel, Senior Scientist, GlaxoSmithKline, UK
"TIDES is an excellent meeting to catch up on the latest efforts in industry on peptide therapeutics and technologies." - Suresh M. Pitram, Senior Research Investigator, Integrated Diagnostics
"Excellent oligonucleotide chemistry, discovery and optimization…" - Steve Shrewsbury, Chief Medical Officer, AVI Biopharma
Copyright IBC Life Sciences, a part of Informa Life Sciences Group. Phone: 800.390.4078 Email: reg@ibcusa.com